Live Breaking News & Updates on Windlass Biotech

Stay updated with breaking news from Windlass biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Glenmark arm, Emcure, 3 other pharma cos line up Rs 7,000-cr IPOs


Amidst the raging second wave of the COVID-19 pandemic and many fearing a third wave, the healthcare sector is in the limelight for the second consecutive year as several pharma and life sciences companies are lined up to tap the equity markets through IPOs over the next few months, according to investment bankers.
Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research.
According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales. ....

United Kingdom , Supriya Lifesciences , Satish Mehta , Glenmark Lifesciences , Emcure Pharma , Satish Waman Wagh , Ajanta Pharma , Deepak Jasani , Aurobindo Pharma , Vinod Nair , Veeda Clinical Research , Bain Emcure Pharmaceuticals , Cx Veeda Clinical Research , Glenmark Pharmaceuticals , Geojit Financial Services , Windlass Biotech , Bain Capital Backed Emcure Pharma , Veeda Clinical , Arti Pharama , Ipca Labs , Gland Pharma , China Plus One , Bain Capital Backed Emcure Pharmaceuticals , Satish Waman , Health Care , Healthcare In India ,